文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

肿瘤学金标准：关于单克隆抗体在头颈部鳞状细胞癌管理中应用的实用共识建议

Oncology Gold Standard practical consensus recommendations for the use of monoclonal antibodies in the management of squamous cell carcinoma of head and neck.

作者信息

Babu Govind, Bahl Ankur, Bhattacharya G S, Bhowmik K T, Dattatraya P S, Ghadyalpatil Nikhil, Karandikar S M, Kulkarni Padmaj, Sridharan Nithya, Parikh Purvish, Prabhash Kumar, Raja T, Rajasundaram S, Subramanian S, Talapatra Kaustav, Vaid Ashok

机构信息

Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India.

Department of Medical Oncology, Max Hospital, New Delhi, India.

出版信息

South Asian J Cancer. 2017 Oct-Dec;6(4):154-160. doi: 10.4103/sajc.sajc_181_17.

DOI:10.4103/sajc.sajc_181_17
PMID:29404293
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5763625/
Abstract

We present the 2017 Oncology Gold Standard Practical Consensus Recommendation for use of monoclonal antibodies in the management of advanced squamous cell carcinoma of head neck region.

摘要

我们提出了《2017年肿瘤学金标准实用共识建议》，用于指导单克隆抗体在头颈部晚期鳞状细胞癌治疗中的应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4d0/5763625/02fdfc2f3694/SAJC-6-154-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4d0/5763625/02fdfc2f3694/SAJC-6-154-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4d0/5763625/02fdfc2f3694/SAJC-6-154-g005.jpg

相似文献

[1]
Oncology Gold Standard practical consensus recommendations for the use of monoclonal antibodies in the management of squamous cell carcinoma of head and neck.

South Asian J Cancer. 2017

[2]
Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines.

Ann Oncol. 2011-5-23

[3]
Management of dermatitis in patients with locally advanced squamous cell carcinoma of the head and neck receiving cetuximab and radiotherapy.

Oral Oncol. 2011-12-3

[4]
Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines.

Radiother Oncol. 2017-11-24

[5]
Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelines.

Oral Oncol. 2013-7-4

[6]
Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.

Semin Oncol. 2002-2

[7]
Oncology Gold Standard™ practical consensus recommendations 2016 for treatment of advanced clear cell renal cell carcinoma.

South Asian J Cancer. 2016

[8]
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.

Lancet. 2018-11-30

[9]
[Study results of primary therapy for head and neck tumors : Highlights of the 2016 ASCO Annual Meeting].

HNO. 2016-10

[10]
Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.

Lancet Oncol. 2015-1-15

引用本文的文献

[1]
An optical aptasensor for real-time quantification of endotoxin: From ensemble to single-molecule resolution.

Sci Adv. 2023-2-10

[2]
Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck.

ESMO Open. 2021-12

[3]
Editorial.

South Asian J Cancer. 2018

本文引用的文献

[1]
Durvalumab: First Global Approval.

Drugs. 2017-8

[2]
Efficacy and toxicity of cetuximab with chemotherapy in recurrent and metastatic head and neck cancer: A prospective observational study.

Indian J Cancer. 2016

[3]
Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline.

Pract Radiat Oncol. 2017

[4]
A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers.

South Asian J Cancer. 2017

[5]
A retrospective analysis of patients with head and neck cancer treated with radiation, hyperthermia, and cetuximab: A brief report of outcome.

J Cancer Res Ther. 2016

[6]
Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial.

JAMA Oncol. 2017-2-1

[7]
Comparison between weekly cisplatin-enhanced radiotherapy and cetuximab-enhanced radiotherapy in locally advanced head and neck cancer: first retrospective study in Asian population.

Asia Pac J Clin Oncol. 2017-6

[8]
Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial.

J Clin Oncol. 2015-12-7

[9]
Chemoradiation in elderly patients with head and neck cancers: a single institution experience.

Am J Otolaryngol. 2015

[10]
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

J Clin Oncol. 2014-9-20

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索